C7A.093 ICD-10-CM Code: Malignant carcinoid tumor of the kidney
C7A.093 maps to CMS-HCC V28 21. A source-labeled RAF reference is available. Confirm the documented diagnosis and applicable coding requirements. MEAT criteria · RAF Calculator · free HCC coding tools
HCC Buddy Code Card
Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.
FY 2026 Apr update / Neoplasms (C00-D49) / Malignant neuroendocrine tumors (C7A)
C7A.093
Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidanceMalignant carcinoid tumor of the kidney
A rare type of cancer that starts in hormone-producing cells of the kidney, growing and spreading to other parts of the body. This is a malignant (cancerous) neuroendocrine tumor that requires immediate treatment.
Buddy Insight
Malignant carcinoid tumor of the kidney is an exceptionally rare neuroendocrine malignancy, with fewer than 100 cases reported in the literature.
CMS-HCC V28
MappedHCC 21
Coefficient HCC 21: 0.671 (Community Non-Dual Aged (CNA))
CMS-HCC V24
HistoricalHistorical
Not used for CY2026 payment
ACA/HHS
MappedHCC 012
Code-level coefficient reference
ESRD/PACE
MappedHCC 12
Code-level coefficient reference
RXHCC
MappedHCC 22
Code-level coefficient reference
Code Book Path
Inclusion Terms
OfficialNo inclusion terms are included in this display for C7A.093. Check the code and parent instructions in the Code Book.
Excludes 2
Official- malignant pancreatic islet cell tumors (C25.4)Inherited from C7A
- Merkel cell carcinoma (C4A.-)Inherited from C7A
Related Codes
Includes
OfficialNo Includes notes are included in this display for C7A.093. Check the code and parent instructions in the Code Book.
Excludes 1
OfficialNo Excludes 1 notes are included in this display for C7A.093. Check the code and parent instructions in the Code Book.
Code First
OfficialNo Code First sequencing instructions are included in this display for C7A.093. Check the code and parent instructions in the Code Book.
Use Additional
Official- code to identify any associated endocrine syndrome, such as:Inherited from C7A
- carcinoid syndrome (E34.00)Inherited from C7A
Code Also
Official- any associated multiple endocrine neoplasia [MEN] syndromes (E31.2-)Inherited from C7A
Buddy Documentation Tip
MEAT Support
Audit Caution
Common Mistakes
Current with CMS: FY2026 ICD-10-CM Apr 1 update (effective Apr 1 – Sep 30, 2026) · CMS-HCC V28, 100% phased in for payment year 2026. FY2027 code set already staged for October 1, 2026. How HCC Buddy stays current →
Is C7A.093 an HCC code?
Yes. C7A.093 (Malignant carcinoid tumor of the kidney) maps to HCC 21, Lymphoma and Other Cancers under the CMS-HCC V28 risk adjustment model, with a source-labeled community non-dual aged reference coefficient of 0.671. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes. It is billable for payment year 2026.
Coder answer: C7A.093 is billable and maps to V28 HCC 21, Lymphoma and Other Cancers. Open it in the Code Book for the tabular path, RAF, and MEAT checklist.
- Code
- C7A.093
- Description
- Malignant carcinoid tumor of the kidney
- HCC (V28)
- HCC 21 — Lymphoma and Other Cancers
- RAF reference coefficient
- 0.671
- Billable
- Yes
- Payment year
- 2026
HCC Category Mapping
These are source-labeled model coefficients, not member totals. A category may still be removed by hierarchy or model cleanup rules. Weights are not directly comparable across models: CMS-HCC V28 and V24 use Community, Non-Dual, Aged; ESRD uses the dialysis continuing-enrollee model; RxHCC is the Part D continuing-enrollee, non-low-income, aged weight (a larger scale than CMS-HCC). ACA/HHS has no single weight — it varies by metal level. Actual per-patient RAF contribution depends on member context, hierarchy and cleanup rules, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains available for historical review.
Work C7A.093 in the Code Book — tabular path, V28 RAF reference, and MEAT checklist →
MEAT review for C7A.093
For C7A.093, confirm that the documentation supports the diagnosis and meets the applicable coding, encounter, program and payer requirements. MEAT (Monitor, Evaluate, Assess, or Treat) is a review mnemonic, not a universal CMS coding rule.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Coder workflow notes
Get the V28 mapping + MEAT cheat sheet
One printable reference: check representative V28 mappings and the documentation reminders your note needs. Free, no card.
Free PDF. No card. Unsubscribe anytime.
What This Code Means
C7A.093 is the ICD-10-CM diagnosis code for malignant carcinoid tumor of the kidney. A rare type of cancer that starts in hormone-producing cells of the kidney, growing and spreading to other parts of the body. This is a malignant (cancerous) neuroendocrine tumor that requires immediate treatment. C7A.093 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neuroendocrine tumors (c7a).
Under the CMS-HCC V28 risk adjustment model, C7A.093 maps to Lymphoma and Other Cancers (HCC 21) with a source-labeled community, non-dual, aged reference coefficient of 0.671. For CY2026 non-PACE Medicare Advantage, CMS uses 100% of the 2024 CMS-HCC model (V28). PACE uses a separate model blend. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes.
Verify documentation specifies the tumor is malignant and located in the kidney; carcinoid tumors can occur in multiple sites and require site-specific coding. For C7A.093, confirm that the documentation supports the diagnosis and meets the applicable coding, encounter, program and payer requirements. MEAT (Monitor, Evaluate, Assess, or Treat) is a review mnemonic, not a universal CMS coding rule. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, source-labeled coefficient references, and MEAT documentation criteria for C7A.093 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Verify documentation specifies the tumor is malignant and located in the kidney; carcinoid tumors can occur in multiple sites and require site-specific coding
- •Ensure the neuroendocrine nature is documented; if metastatic disease is present, code the secondary sites separately using C7A codes or C80 codes as appropriate
Clinical Significance
Malignant carcinoid tumor of the kidney is an exceptionally rare neuroendocrine malignancy, with fewer than 100 cases reported in the literature. Renal carcinoids must be distinguished from the far more common renal cell carcinoma. These tumors can produce vasoactive substances and may present with carcinoid syndrome, though this is uncommon in renal primaries. The rarity of this diagnosis necessitates careful pathologic confirmation.
Documentation Requirements
- ✓Pathology report with immunohistochemical staining confirming neuroendocrine differentiation (synaptophysin, chromogranin A positive)
- ✓Distinction from renal cell carcinoma, collecting duct carcinoma, or metastatic neuroendocrine tumor to the kidney
- ✓Laterality (right or left kidney)
- ✓Tumor size and staging
- ✓Presence or absence of metastatic disease at other sites
- ✓Treatment plan and surveillance protocol
Commonly Confused Codes
- •C64.9: Malignant neoplasm of unspecified kidney: Use for renal cell carcinoma and other non-neuroendocrine kidney cancers
- •C7B.09: Secondary carcinoid tumors of other sites: Use when carcinoid from another primary has metastasized to the kidney rather than a primary renal carcinoid
- •D3A.093: Benign carcinoid tumor of the kidney: Use only for confirmed benign neuroendocrine tumors of the kidney